Details

Last Funding Type

Series B

Last Funding Money Raised

€11M

Industries

Biopharma,Biotechnology,Health Care,Life Science,Medical,Medical Device

Founded date

Jan 1, 2017

Number Of Employee

11 - 50

Operating Status

Active

PredictImmune is developing pioneering tools for guiding treatment options in immune-mediated inflammatory diseases with the first product addressing Inflammatory Bowel Disease (both Crohn’s and ulcerative colitis).
Based on world-leading research at Cambridge University, UK, they are developing a simple lab test, using a small blood sample, which accurately identifies patients at diagnosis who are at risk of experiencing severe, relapsing disease. These patients are likely to benefit from early biologics therapy. Physicians, patients and payors all recognise the value of such an approach to the management of Inflammatory Bowel Disease.